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Tau protein can transfer between neurons transneuronally and trans-synaptically, which 21 
is thought to explain the progressive spread of tauopathy observed in the brain of 22 
patients with Alzheimer’s Disease.  Here we show that physiological tau released from 23 
donor cells can transfer to recipient cells via the medium, suggesting that at least one 24 
mechanism by which tau can transfer is via the extracellular space.  Neuronal activity 25 
has been shown to regulate tau secretion, but its effect on tau pathology is unknown. 26 
Using optogenetic and chemogenetic approaches, we found that increased neuronal 27 
activity stimulates the release of tau in vitro, and enhances tau pathology in vivo.  These 28 
data have implications for disease pathogenesis and therapeutic strategies for 29 
Alzheimer's disease and other tauopathies.  30 
 31 
Misfolded, hyperphosphorylated forms of the microtubule stabilizing protein tau 32 
accumulate as neurofibrillary tangles in Alzheimer’s disease (AD).  In the earliest stages 33 
of the disease, tau is found in the somatodendritic compartment of neurons located in 34 
the transentorhinal cortex (EC)1. Tau pathology spreads medially and worsens in the 35 
EC; it then accumulates within limbic areas, followed by neocortical areas in a pattern 36 
that suggests spread along neuroanatomical connections1.  Various mouse models 37 
have been created to replicate the progressive spread of pathology including those 38 
using regional promoters2-4, inoculation models5-9 and viral models10,11 and it is now well 39 
established that tau has the capability to transfer between cells both in vivo and in 40 
vitro8,12. Two hypotheses have been proposed to explain the propagation of tau 41 
pathology. First, intracellular tau could transfer directly between cells through physical 42 
connections such as tunneling nanotubes, as shown in vitro for misfolded proteins such 43 
as prion13.  Alternatively, tau could be released into the extracellular space, either as 44 
free tau or within vesicles such as exosomes14-16 or ectosomes17. Data showing that tau 45 
is present in the cerebrospinal fluid (CSF) and interstitial fluid (ISF) of tau transgenic 46 
mouse lines18-20 and the CSF and ISF of AD brain21 together with data showing tau is 47 
released into the medium of cultured neurons22 support the second hypothesis. 48 
Although there is strong evidence that tau is released from cells, the competence of 49 
extracellular tau generated in vitro, by neurons, to contribute to cell to cell propagation 50 
has not been tested. Using physiologically relevant culture systems, including human 51 
iPSCs, we have shown that tau released from donor cells into the medium can be 52 
internalized by recipient cells where it can stimulate the generation of more aberrant 53 
tau.  Furthermore, using a tripartite microfluidic system, we have shown that the 54 
aberrant tau generated in recipients can be passed to subsequent recipient cells 55 
indicating true propagation.   56 
  57 
The mechanism by which tau can be released from neurons is unknown, however its 58 
release can be stimulated by enhanced neuronal activity both in vitro22 and in vivo23.  As 59 
cells within the AD13 brain could be hyperexcitable 24-28, the impact of enhanced 60 
neuronal activity on tauopathy is of significant interest. Using sophisticated optogenetic 61 
and chemogenetic manipulations we have demonstrated that increasing neuronal 62 
activity can not only enhance release and transfer of tau in vitro, but also exacerbate tau 63 
pathology in vivo.  64 
 65 
 66 
Results 67 
Endogenously generated tau transfers from cell to cell  68 
To examine whether physiologically relevant, human tau (hTau) can transfer between 69 
neurons, we cultured neurons derived from a transgenic mouse line expressing hTau 70 
P301L (line rTg4510, “donor”)29 with neurons from a MAPT–/–:GFP (tau knockout-GFP 71 
line (KO, “recipient”)30 (Fig. 1a). After 2 weeks, hTau accumulated in the cytosol and 72 
neurites of recipient cells grown on plates (Fig. 1b, cell C) and in microfluidic chambers 73 
(MFs, Fig. 1c, arrows).  To determine whether highly aggregated forms of tau have a 74 
greater propensity for neuron-to-neuron transfer, we compared the effects of two types 75 
of seeds on tau transfer; clone 9 seeds that have been shown to induce the formation of 76 
robust aggregates of tau, or clone 1 seeds that do not induce the formation of 77 
aggregates of tau8. In this experiment, the tau that is expressed in donor cells was 78 
fluorescently tagged (repeat domain RD P301S YFP) so that it could be directly 79 
visualized within the recipients. Lysate containing clone 1 seeds did not readily induce 80 
any obvious aggregates in donor cells even after extensive culturing (20 days in vitro).  81 
In contrast, when lysate containing clone 9 seeds was added, YFP-tagged endogenous 82 
tau began forming perinuclear aggregates in cells after 5 days in vitro (DIV).  The 83 
number of cells forming tau aggregates increased dramatically after 20 DIV, 84 
demonstrating that template induced tau aggregation is time-dependent (Fig. 2a).  To 85 
assess whether induced tau aggregates were transferred to recipients, seeded donor 86 
cells were co-cultured with mCherry-expressing recipient neurons. YFP-tau from clone 9 87 
seeded cells, but not clone 1 seeded cells readily accumulated in the cytoplasm of 88 
recipient cells (Fig. 2b, cell A, B; Fig. 2c). Controls included neurons expressing YFP 89 
but no tau, co-cultured with neurons expressing mCherry.  In the absence of tau, no 90 
transfer of YFP or mCherry was seen (data not shown).   91 
 92 
To test whether aggregate formation can be induced in downstream cells, we turned to 93 
a bi- and tripartite microfluidic chamber device (Figs. 3a,d).  The chambers allow axons 94 
from one compartment to grow through microchannels into an adjacent compartment 95 
while isolating cell bodies and dendrites within one compartment.  Importantly, the 96 
fluidically isolated microenvironment in each chamber allows for the delivery of agents 97 
such as seeds to one cell population without crossing over into the next 98 
compartment9,31. RD YFP neurons were grown in each chamber. Unseeded tau 99 
expressing cells did not form visible aggregates (Fig. 3b); however, adding clone 9 100 
seeded lysate to cells in the first compartment (population 1) induced endogenous YFP-101 
tagged tau to form aggregates (Fig. 3c).  Endogenous tau in neurons grown in the 102 
second compartment (population 2) formed aggregates after 12-15 DIV in response to 103 
aggregated tau being formed and transferred from population 1 (Fig. 3c). To confirm 104 
true cell-to-cell tau propagation, we utilized tripartite MFs and added seed-containing 105 
lysate only to neurons in the first compartment (population 1). We then examined 106 
whether tau aggregates could propagate not only to the second compartment 107 
(population 2), but also to the third compartment (population 3) (Fig. 3d). After 15-18 108 
DIV, tau aggregates were found in some population 3 neurons (Fig. 3e).  The misfolded 109 
conformation of these aggregates was confirmed by staining with X-34, a fluorescent 110 
congo red derivative that binds to neurofibrillary tangles (Fig. 3f)32.   111 
 112 
Tau transfers to recipients via the extracellular medium 113 
We next examined whether tau transfer from donor neurons to recipient neurons 114 
requires cell-to-cell contact, or if tau released into the extracellular fluid is sufficient. 115 
Lysate and conditioned medium (CM) from primary neurons overexpressing tau, or 116 
neurons infected with tau virus was collected, tau was immunoprecipitated using a 117 
human tau specific antibody and analyzed by western blot analysis.  Tau was detected 118 
in the media of both cell models (Fig. 4a).  Actin was present in lysates but absent in 119 
media fraction demonstrating that the media was not contaminated with cell debris.  120 
Next, we incubated wild-type (wt) recipient neurons with CM from hTau-expressing 121 
donor cells for the following incubation periods: 1 hour, 6 hours, 12 hours, 1 day or 6 122 
days. Recipient neurons accumulated tau within hours and had a significant amount of 123 
tau accumulation by 6 days (Fig. 4b). Immunofluorescence staining revealed that the 124 
internalized tau initially accumulated in discrete puncta in the cytosol and dendrites of 125 
recipient neurons after 2 days (Fig. 4c) but it later appeared more diffusely distributed in 126 
cell bodies and neurites (Fig. 4c). To confirm that tau was released into the medium 127 
from cells expressing it at physiological levels, we examined induced pluripotent stem 128 
cells (iPSC) that were differentiated into cortical neurons by dual SMAD inhibition 129 
followed by an extended period of in vitro corticogenesis (Figs. 4d,e)33.  In vitro 130 
corticogenesis using this method has been shown to take up to 90 days, producing all 131 
classes of glutamatergic projection neurons that make mature, functional synapses that 132 
are capable of firing repetitive action potentials34.  Immunoblotting of whole cell lysates 133 
at time points throughout differentiation (Fig. 4d) showed a single band that was 134 
immunoreactive for tau at all time points from day 20 onwards.  Comparison with a 135 
recombinant tau ladder confirmed this was the 0N3R tau isoform, consistent with 136 
previous reports that iPSC-neurons mainly express fetal tau isoform and not the adult 137 
isoform ratio of equivalent 3R:4R35.  Cortical progenitor rosettes positive for the early 138 
forebrain marker Pax6 and the proliferation marker Ki67 were observed at day 20 of 139 
differentiation (Fig. 4e).  At this time point, tau was observed in a subset of cells but it 140 
did not colocalize with Ki67, suggesting that tau expression is restricted to post-mitotic 141 
neurons.  By day 100 of differentiation, the majority of cultured cells showed stereotypic 142 
neuronal morphology such as high levels of tau expression and extended neurites. To 143 
assess whether tau could be internalized, we transferred CM from iPSCs to mouse 144 
primary wt neurons. After six days, human tau was observed in the neurites of the 145 
recipient cells with a similar distribution pattern to the tau generated by the transgenic 146 
mouse neurons (Fig. 4f).  This result is consistent with a recent finding showing tau 147 
from mouse and human brain extracts, and the ISF from the rTg4510 line are 148 
internalized by recipients20.  149 
 150 
Neuronal activity stimulates tau release and spread  151 
Increased neuronal activity has been shown to stimulate tau release in wild type and 152 
human tau-overexpressing transgenic mouse models in vitro22 and in vivo23, however, it 153 
is not known if stimulation leads to release of tau from human neurons with 154 
physiological levels of tau. To examine this, we measured the amount of tau released 155 
into media from human iPSC neurons, as well as murine tau expressing neurons (wild 156 
type) and neurons overexpressing mutant human tau (rTg4510 line), before, and after 157 
treatment with picrotoxin, a non-competitive channel blocker for the GABA receptor 158 
chloride channels36 (Fig. 5a).  In all three systems, stimulation with picrotoxin increased 159 
tau in the media by 150% - 210% compared to tau levels in the media prior to the 160 
addition of picrotoxin, or compared to media from neurons treated with buffer alone, 161 
without causing cell death (Fig. 5b).  To examine whether increasing neuronal activity 162 
leads to enhanced tau release, we used an optogenetic approach in one of our culture 163 
models to directly stimulate neuronal action potentials37. Cells expressing 164 
channelrhodopsin (ChR2) can be depolarized by exposure to blue light at 473 nm 165 
wavelength.  Primary neurons from a wt mouse were transfected with fluorescently 166 
tagged hTau and ChR2 expressing viral vectors (Figs. 5c,d).  Media was removed and 167 
analyzed for human tau levels before, and after light stimulation.  Whole cell recording 168 
was performed simultaneously to confirm activation (Figs. 5e,f).  After neurons were 169 
stimulated for 30 min (0.1 mW mm-2, 2 s intervals), tau in the media increased 170 
approximately 250% (Fig. 5g), similar to the amount of tau released from neurons 171 
following picrotoxin treatment (Fig. 5a).  Optogenetic stimulation did not result in cell 172 
death as shown by patch clamp recording of individual cells (Figs. 5e,f) and more 173 
globally, by lactate dehydrogenase (LDH) assessment (Fig. 5h).  To test whether 174 
stimulating neuronal activity can enhance cell-to-cell transfer of tau in addition to tau 175 
release, we added picrotoxin to co-cultures of neurons that made hTau aggregates (RD 176 
YFP with C9 seeded lysate) or mCherry (Fig. 6), and quantified the percent of mCherry 177 
cells containing YFP tau aggregates. After two weeks of co-culturing, neurons were 178 
fixed and examined using confocal microscopy (Fig. 6a). Quantification of IF images 179 
demonstrated that stimulating neuronal activity increased the percentage of cells that 180 
had taken up tau from approximately 20% of mCherry cells to 45% of mCherry cells 181 
(Fig. 6b). 182 
 183 
Enhanced neuronal activity accelerates tauopathy in vivo 184 
Tau has been shown to accumulate in the ISF following administration of picrotoxin in 185 
vivo23, however it is not known if enhancing neuronal activity accelerates tauopathy. To 186 
address this important question, we used two approaches to increase neuronal activity 187 
in two different tau mouse models.  Using an optogenetic approach, ChR2 was 188 
expressed in neurons under the CamKII promoter37 for 10 days and optical fibers were 189 
implanted in both left and right hippocampi of the rTg4510 line, but only the left 190 
hippocampus was stimulated with blue light (470 nm). Tau pathology in the left 191 
(stimulated) hemisphere was compared to the right (non stimulated) hemisphere (Fig. 192 
7a).  In vivo recordings confirmed that blue light induced an increase in hippocampal 193 
activity (Fig. 7b).  Neuronal firing in response to blue light ON was instantaneous with 194 
minimal time lag (<10 ms) and the firing rate approximately doubled during stimulation. 195 
When the blue light was OFF, the firing rate returned to normal. The EEG and spike 196 
firing pattern did not show any epileptic-like phenotype and seizures were not observed 197 
(data not shown). Recording from the right hemisphere showed that ChR2-controlled 198 
firing did not lead to firing in the non-stimulated hemisphere (data not shown).  After 20 199 
days of stimulation, mice were sacrificed within 75 mins of the last stimulation, and the 200 
brain tissue was processed for immunolabeling of the activity-induced immediate early 201 
gene, c-Fos, which was readily observed in the stimulated hippocampus (Fig. 7c).  202 
When immunolabeled with anti-tau antibodies, we observed that the stimulated 203 
hippocampus had accumulated more human tau (labeled with TauY9 and CP27 204 
antibodies) in the cell bodies. This was particularly evident in the posterior and anterior 205 
planes, especially in CA1 and CA3 pyramidal cells, (Figs. 7d,e, insets) which was 206 
consistent with the placement of the optical fiber.  Enhanced tau pathology was 207 
accompanied by hippocampal cell layer atrophy (Fig. 7e) that was more evident in brain 208 
tissues stained using Nissl (Fig. 7f,h).   Optogenetic stimulation using the same 209 
parameters did not result in detectible atrophy in mice without tauopathy (a MAPT–/– 210 
line (Figs. 7g,h) suggesting the stimulation itself was not causing the atrophy.   To 211 
ensure that enhanced tauopathy was not due to enhanced expression of the transgene, 212 
we performed quantitative RT-PCR on both stimulated and non-stimulated hippocampal 213 
tissue from mice stimulated for 20 d.  While there was variable human tau expression 214 
between mice, we did not detect differences in tau expression between hemispheres of 215 
rTg4510 mice (Supplementary Fig. 1).  216 
To confirm our results using a different stimulation approach, in a different mouse line, 217 
we used the Designer Receptor Exclusively Activated by Designer Drug (DREADD)38 218 
chemogenetic approach to transiently stimulate neurons in the entorhinal cortex (EC) of 219 
the EC-Tau mouse line2.  The clozapine-n-oxide (CNO)-responsive DREADD (CaMKIIa-220 
hM3D(Gq)-mCherry) was expressed in the left EC and a receptor that was 221 
unresponsive to CNO (CaMKIIa-ChR-mCherry) was expressed in the right EC as a 222 
control.  The DREADD was expressed in the MEC for at least 10 days before 223 
stimulation, and viral expression remained stable for at least 6 weeks (Fig. 8a).  CNO 224 
administration enhanced neuronal activity in the MEC approximately 20 min post 225 
injection without causing seizures, as shown by in vivo electrophysiology (data not 226 
shown), and enhanced c-Fos labeling in the stimulated EC compared to the non-227 
stimulated EC (Fig. 8b). After 6 weeks of CNO administration, we observed increased 228 
accumulation of somatodendritic tau (antibody MC1) in neurons in the stimulated EC as 229 
compared to the non-stimulated EC of the same mouse (Fig. 8c, outlined, arrows, 230 
insets, low laser power images). Stimulation for 2 weeks also showed enhanced 231 
tauopathy, but to a lesser degree (Supplementary Fig. 2a).  Images taken using higher 232 
laser power demonstrated that the increase in somatodendritic tau was most evident in 233 
the EC region where DREADD virus was expressed whereas tau pathology in other 234 
regions (for example the granule cells of the dentate gyrus) did not show any obvious 235 
enhancement (Fig. 8c).  A similar enhancement of tau pathology was observed using a 236 
second human specific tau antibody, CP27 (Supplementary Fig. 3b, arrows).  Non-237 
specific staining was not observed when the secondary antibody was used in the 238 
absence of the primary antibody (data not shown).  239 
 240 
Discussion  241 
Using a variety of in vitro cell models, we have shown that 1) neuron-derived full-length 242 
tau can transfer to recipients and that aggregated tau induced by seeding transfers 243 
efficiently, 2) that neuron-derived tau can not only be internalized by recipient neurons, 244 
but it can undergo transcellular propagation to distant cells, and 3) that neuron-derived 245 
tau (including tau from human iPSCs) can transfer to recipients via the extracellular 246 
space.  Several studies have shown internalization of exogenously-added tau8,9,12,39,40 247 
into recipient cells, while more recent studies show that endogenously generated tau 248 
can also be internalized, including tau that was released into the extracellular space 249 
either in conditioned medium from mutant tau expressing SH-SY5Y cells41 or the ISF 250 
from rTg4510 mice23.  In our study we found that non-mutant tau from wt mice and from 251 
non-mutant human iPSCs can also be released and internalized.  Tau in these cells 252 
does not form overt, morphologically distinct aggregates even when cultured for long 253 
periods of time (over 20 days, data not shown), suggesting that the majority of tau 254 
released from these neurons is likely to be soluble which is consistent with a study that 255 
showed that soluble tau is released into the medium of cells22, the ISF of transgenic and 256 
wt mice18,23, and the ISF of an anti-aggregating mouse model42. Whether the soluble tau 257 
from wt neurons or iPSCs is monomeric or oligomeric is unknown.  Exogenously added 258 
monomeric tau can be internalized41 but in our experience9, it does not accumulate to 259 
any degree.  It is possible, especially for neurons from the rTg4510 line, that small, early 260 
stage misfolded tau oligomers have formed in the cultures that are not readily 261 
discernable by morphology, nor by dyes such as X-34 that recognize more aggregated 262 
beta-sheet structures and that these oligomers are released into the media and taken 263 
up by recipient neurons.  What is clear from our seeding experiments however is that 264 
higher order aggregated forms of tau can accumulate in recipients more readily. A 265 
recent study23 has examined the uptake of tau from brain extract and has shown that a 266 
low abundance, higher molecular weight, phosphorylated form of tau is internalized and 267 
propagates. The same study showed that both high and low molecular weight tau is 268 
present in the ISF from rTg4510 mice, and while tau in the ISF was shown to be 269 
internalized by recipients, it is not known if it was the same type of tau that was 270 
internalized from the lysate.  In our experience, tau released from cells making 271 
aggregates promotes propagation much more robustly than tau from neurons making 272 
soluble tau. Taking advantage of this, we have now shown that tau aggregates 273 
generated within one population of neurons can induce tau misfolding (X-34 positive 274 
aggregates) in a fluidically isolated, second- and third population of neurons cultured in 275 
microfluidic chambers.  276 
 277 
The fact that tau can be transferred between cells via the media suggests that 278 
structures such as tunneling nanotubes are not required, at least not for in vitro transfer 279 
(in vivo transfer mechanisms are not known). We do not yet know whether tau in the 280 
media is vesicle bound or free. Exogenously added free (recombinant) tau12,39,43 281 
including oligomers9 has been shown to be internalized by bulk endocytosis, and uptake 282 
can be mediated by binding to heparan sulfate proteoglycans43. Exogenously added tau 283 
in cell or brain extract can also be internalized by recipient cells8,44,45, but it is not known 284 
whether it is free or vesicle-bound in these preparations.  A small proportion of tau 285 
released from cells (for example, into the ISF of wt tau overexpressing rodents17) has 286 
been identified in vesicles (ectosomes and to a lesser extent exosomes). Tau has only 287 
been found in ectosomes, and not exosomes when it is expressed at physiological 288 
levels17. Importantly, using wt neurons and iPSCs we have shown that tau release and 289 
internalization can occur without overexpressing tau.  How internalized tau accesses 290 
endogenous tau to enable templating is currently unknown but the creation of more 291 
physiologically relevant models of tau release, internalization and propagation such as 292 
those described here will allow us to address these questions better. Taken together, 293 
our data show that endogenously produced tau aggregates are released and can 294 
induce subsequent misfolding and seed formation in downstream neurons, resulting in 295 
cell-to-cell propagation that could explain the widespread distribution of tau pathology in 296 
AD.  297 
 298 
One of the observations from transgenic mice overexpressing the amyloid precursor 299 
protein (APP) is that elevated amyloid beta (Aβ) is somehow associated with 300 
hyperexcitability at the cellular level24-28.  The observation that cellular hyperexcitability 301 
can stimulate the release of tau in vitro22 and in vivo23  suggests that in humans, Aβ-302 
induced hyperexcitability within regions of the brain that are vulnerable to early 303 
tauopathy, such as the hippocampal formation, could lead to enhanced release of 304 
pathogenic tau and accelerated propagation of tauopathy through circuits. In support of 305 
this, we have shown that optogenetically stimulated tau mice undergo robust worsening 306 
of pathology (accumulation of cell body tau) in the stimulated hippocampus. Of note, the 307 
worsened pathology appears to be neurotoxic as it correlated with exacerbated 308 
hippocampal cell layer atrophy.  The EC-tau mouse model, when stimulated 309 
chemogenetically, demonstrated worsening tauopathy in the stimulated entorhinal 310 
cortex.  Additional pathology in cell populations that are synaptically connected with the 311 
EC such as the dentate gyrus granule cell layer was not obvious. However, in the EC-312 
tau line, the accumulation of tau in the granule cell layer is a slow process, which takes 313 
more than 18 months to become apparent2. In our experiments, the EC was stimulated 314 
for a maximum of 6 weeks, starting at an age when pathology was mild. More time may 315 
be needed to effectively induce tau propagation into the granule cells of the dentate 316 
gyrus, or the mice may need to be at a more advanced stage when first stimulated for it 317 
to become apparent within the relatively short timeframe.  In general, these data have 318 
several implications. Firstly, they may have relevance for AD where therapeutic 319 
approaches to dampen down excitability46-48 may retard the spread of tau pathology, 320 
which, if performed during the earliest Braak stages, could prevent the onset of 321 
cognitive decline.  Second, these results may explain the observation of tauopathy 322 
associated with epileptic seizures, although the link between brain injury and tauopathy 323 
obscures the relationship49.  Lastly, there may be negative implications for stimulation 324 
therapies such as deep brain stimulation (DBS), or transcranial magnetic stimulation 325 
(TMS) that are currently in clinical trials for AD patients.  326 
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  514 
Figure Legends 515 
Figure 1. Endogenously generated human tau can transfer from cell to cell.  (a) Cartoon 516 
model showing co-cultures of neurons on coverslips and in microfluidic chamber 517 
devices.  Co-cultures of mutant hTau-expressing (red, from rTg4510 line, cell A) and 518 
recipient KO neurons (green, from KO line, cells B, C). (b) hTau in recipient KO cell (cell 519 
C, yellow) on coverslip and (c) in MFs (yellow, arrows). Scale bars, 10 and 50 µm, 520 
respectively.  Images are representative of four neuronal cultures.  521 
Figure 2. Endogenously generated human tau aggregates can transfer from cell to cell.  522 
(a) Tau repeat domain-expressing neurons (hTau RD P301S-YFP, green) do not readily 523 
form aggregates when exposed to PBS or clone 1 lysate after 20 DIV.  Clone 9 lysate 524 
seeded tau cells start forming aggregates (arrow) at 5 DIV and increase after 20 DIV.  525 
Scale bar, 50 µm. (b) Seeded tau RD aggregates (green) transferred to recipient cells 526 
(mCherry, red) (cell A, B, yellow).  Scale bar, 10 µm. (c) Enlarged orthogonal view of 527 
cell A showing transferred tau in the cytoplasm of the cell.  Images are representative of 528 
four neuronal cultures. 529 
Figure 3. Seed-induced tau pathology propagates from cell to cell.  (a) Cartoon model 530 
showing co-cultures in microfluidic devices with two chambers.  (b) Unseeded tau-531 
expressing cells (population 1, 2) grown in bipartite chamber device do not form visible 532 
aggregates.  (c) Seeding population 1 with clone 9 lysate triggered endogenous tau to 533 
form aggregates in population 1 and population 2. Images are representative of three 534 
cultures. (d) Cartoon model showing co-cultures in microfluidic devices with three 535 
chambers. (e) Pathology propagated from population 1 cells to population 3 cells grown 536 
in tripartite chambers.  Scale bars, 100 µm.  Enlarged images show tau aggregate-537 
containing neurons in population 1, 2 and 3.  Images are representative of two cultures. 538 
(f) Tau aggregate-containing neurons from populations 1, 2, and 3 stained with X-34.  539 
 540 
Figure 4. Tau from mouse primary neurons and human iPSCs can transfer via the 541 
extracellular medium (a) Lysate from rTg4510 primary neurons and P301L-GFP 542 
transduced neurons, and conditioned media from the same cells, labeled with TauC 543 
(full-length blots shown in Supplementary Figure 4).  Actin shows equal amounts of 544 
protein loaded. (Full-length blots shown in Supplementary Figure 4.) (b) ELISA using 545 
tau-specific antibodies showing uptake of tau from media by tau-KO cells.  Compared to 546 
controls (n = 4 cultures), tau was significantly higher in neurons after 1-6 hours of 547 
incubation with tau-conditioned media (n = 6, z = -2.558, adjusted P = 0.021) (left), and 548 
also after 1-6 days of incubation (n = 4, z = -2.309, adjusted P = 0.042).   (c) Neurons 549 
(wild-type), incubated with rTg4510 conditioned media for 2 and 6 days (d), labeled with 550 
anti-tau antibody (green) and anti-MAP2 (red).  Insets show tau in cell bodies and 551 
neurites.  (d) Total tau in human iPSC neuron lysates.  Recombinant tau ladder (R) 552 
separates in the following order of decreasing molecular weight: 2N4R, 2N3R, 1N4R, 553 
1N3R, 0N4R, 0N3R. The single tau band corresponds to the 0N3R isoform.  (e) iPSC 554 
cultures immunolabeled with the early forebrain marker Pax6 and tau, which was only 555 
expressed in post-mitotic neurons.  By day 100 of differentiation, the majority of the cells 556 
in culture were immunoreactive for total and 3R tau. Scale bar, 100. (f) Neurons (wild-557 
type) treated for 6 d with tau conditioned media collected from iPSC neurons, stained 558 
with antibodies (anti-tau, green, anti-MAP2, red) and DAPI (blue).  Enlarged insets show 559 
tau (green) accumulating inside neurites (yellow). Scale bar, 10 µm.     560 
Figure 5. Tau release is enhanced by stimulating neuronal activity. (a) Sandwich ELISA 561 
showed that tau is released into the media from cultured cells (mTau, n = 9 cultures per 562 
treatment group; hTau + mTau, n = 9 cultures per treatment group; hTau, human and 563 
iPSC neurons, n = 6 cultures per treatment group), when treated with picrotoxin for 30 564 
min. Raw data was normalized to baseline levels for each cell population, and plotted as 565 
the percent change. A significant difference was observed between treated and 566 
untreated groups for each model: mTau t(9.167) = -4.75, Bonferroni adjusted P =0.003; 567 
hTau + mTau t(16) =  -7.25, adjusted P < 0.0001; hTau t(10) = -2.95, adjusted P = 568 
0.044. (b) No significant difference was observed between treated and untreated groups 569 
in LDH release. Group n’s were as above. P values from adjusted t-tests = 0.73, 0.061, 570 
and 0.233. (c) Transduced neurons co-express both tau (green) and ChR2 (red). (d) 571 
Tau and ChR2-expressing neuron was patch-recorded and (e) exhibited ~5 mV 572 
depolarization of membrane potential (RMP) with light stimulation at 30 Hz. (f) Light at 573 
470 nm, but not 570 nm caused a 12mV depolarization in ChR2-cells. (g) Significant 574 
difference in tau released after stimulation (30 min) (n = 4 cultures per condition) 575 
(Kruskal-Wallis χ2(2) = 7.42, P = 0.024) with significantly higher tau in stimulated cells 576 
compared to non-stimulated (adjusted P = 0.036) and control neurons (adjusted P = 577 
0.021). (h) LDH release measured before and after treatment did not differ significantly 578 
χ2(2) = 0.731, P = 0.694 (n = 4 cultures per condition). 579 
Figure 6. Transfer of tau from cell to cell is enhanced by stimulating neuronal activity. 580 
(a) Images showing tau protein (green) from tau-expressing donor cells in recipient 581 
mCherry cells (red) (merged in yellow) seeded with clone 9 lysate. Data shows cells 582 
without, and with picrotoxin (+PTX) stimulation. Scale bar, 50 μm. (b) Tau transfer, as 583 
determined by the number of mCherry cells containing tau, as a percentage of the total 584 
number of mCherry cells, was significantly higher in the stimulated group (n = 5) 585 
compared to the unstimulated group (n = 5); t(8)= -2.68, P = 0.028.   586 
Figure 7. Increased neuronal activity induced optogenetically exacerbates tau 587 
pathology in the hippocampus.  (a) In vivo optogenetic stimulation: Cartoon shows the 588 
experimental setup. Tau expressing mice (rTg4510) were injected with ChR2 589 
expressing vector and implanted with optical fibers in both hemispheres; in some mice a 590 
recording electrode was also inserted in one or both hemispheres. (b) Extracellular 591 
recordings show that pulses of blue light (blue bars) increased the firing activity 592 
consistently. The same neurons could be recorded longitudinally demonstrating that 593 
chronic, repetitive stimulation did not impact cell viability. Red boxed inset: zoom-in of 594 
stimulation #15. Bottom row: example waveforms from stimulated (green inset) vs. 595 
unstimulated (black inset) neurons.  (c) Representative image of c-Fos immunostaining 596 
(d) Brain tissues of stimulated mice labeled with anti-tau antibody (TauY9, green) Scale 597 
bar, 500 µm. n = 2 mice.  White boxed inset: enlargements of CA1 and 3.  (e) Posterior 598 
and anterior tissues labeled with anti-tau antibody (CP27, green) shows more tau 599 
pathology (arrows, red) in the stimulated side.  Red boxed inset: enlargements of 600 
anterior hippocampus. (f, g) Nissl stain of brain tissues of stimulated tau mouse and 601 
tau-KO (KO-GFP line) shows reduced cell body staining, especially in the hippocampus. 602 
Scale bar, 500 µm.  n = 4 mice for each line.   (h) Assessment of Nissl stain signal of 603 
hippocampal pyramidal cell layers shows significant reduction in the stimulated 604 
hemisphere of the tau mice (n = 4) but not the tau-KO mice (n = 4 mice, z = 2.31, P = 605 
0.021).  S = stimulated hemisphere, NS = non-stimulated hemisphere.   606 
Figure 8. Increased neuronal activity induced chemogenetically accelerates tau 607 
pathology in the EC. (a) CaMKIIa-hM3D(Gq)-mCherry (red) was injected and expressed 608 
in the MEC of the left hemisphere of EC-Tau mice.  (b) Representative image of c-Fos 609 
immunostaining.  Scale bar, 100 µm. (c) Representative image of brain tissues of mice 610 
stimulated for six weeks labeled with an antibody against pathological human tau (MC1, 611 
green), anti-NeuN (magenta) and DAPI (blue).  Inset: Enlarged images from the 612 
entorhinal cortex (EC) and the dentate gyrus (DG) of stimulated and non-stimulated 613 
hemispheres.  Red arrows, somatodendritic tau in neurons of the EC.  Magenta arrows, 614 
tau in granule cells of the DG.  DAPI (blue).  Scale bar, 500 µm, n = 3 mice. S = 615 
stimulated hemisphere.  NS = non-stimulated hemisphere.   616 
Supplementary Figure 1. Increased neuronal activity does not change human tau 617 
expression in the stimulated mice (line rTg4510, n = 6). To adjust for total neuron count, 618 
the expression ratio of hTau/NeuN was plotted for animals 1- 6.  There was no 619 
significant difference between stimulated (mean ratio = 1.92 ± 1.28) versus non-620 
stimulated (mean ratio = 2.43 ± 1.54) hemispheres; t(5) = -1.57, P = 0.18. 621 
Supplementary Figure 2.  Immunohistochemistry image of brain tissue of two-week 622 
stimulated EC-Tau mice stained with anti-human tau antibody, MC1 (green).  DAPI 623 
(blue).  Scale bar, 500 µm, n = 1 mouse. 624 
Supplementary Figure 3.  Immunohistochemistry image of brain tissue of six-week 625 
stimulated EC-Tau mice stained with (a) anti-human tau antibody, MC1 (green) 626 
acquired using lower green laser power, or (b) CP27. DAPI (blue).  Scale bar, 500 µm, 627 
n = 3 mice. 628 
Supplementary Figure 4.  Full-length images of western blots presented in Fig. 4a.  629 
Lysates from tau-expressing neurons (rTg4510 primary neurons and P301L-GFP 630 
transduced neurons) and conditioned media from the same cells was 631 
immunoprecipitated with anti-hTau antibody (CP27) and analyzed by immunoblot with 632 
total tau antibody (TauC).  Actin shows amounts of protein loaded and absence of cell 633 
contamination in conditioned media.  634 
 635 
Methods 636 
Transgenic mice. Protocols and procedures were approved by the Committee on the 637 
Ethics of Animal Experiments of Columbia University and according to Guide for the 638 
Care and Use of Laboratory Animals of the National Institutes of Health. Mouse models 639 
used in this study included: rTg4510 (CAMKII:hTau-P301L, embryonic day 15-16 for 640 
culture, 2-4 months for in vivo studies, parental lines were a gift of K. Hsiao22, MAPT–/– 641 
GFP (Tau-KO-GFP) (embryonic day 15-16, parental line was a gift of K. Tucker)30, Tau-642 
KO (Jackson Labs), and EC-Tau (neuropsin-tTA, hTau-P301L line r4510, 12-14 643 
months, parental lines were a gift of M. Mayford and K. Hsiao)2. Both male and female 644 
mice were used for each in vivo experiment.  Strains of mice were C129/FVB F1 645 
(rTg4510), C57blk6 (hTau, tau KO). 646 
Neuronal culture.  Primary neuronal cultures were prepared and maintained as 647 
previously described9.  For co-cultures, hippocampal and cortical neurons were isolated 648 
from male and female rTg4510 and Tau-KO-GFP mouse lines, plated into separate 649 
reservoirs of the MFs or together at 1:1 ratio on coverslips.  For co-cultures of 650 
transduced neurons, male and female wild type rat primary neurons were plated in MFs 651 
and then transduced at 3-5 DIV with either mCherry (1:1000) or tau-GFP (hTau-P301L-652 
GFP or GFP alone, 2 x 109 particles), or RD P301S YFP (1:10) vectors. Amounts of tau 653 
protein generated in cultured neurons was as follows: P301L GFP transduced neurons: 654 
9.28 ± 0.675 ug mg (tau per total protein) (n = 3 cultures); rTg4510 neurons:  7.84 ± 655 
1.97 ug mg (tau per total protein) (n = 12 cultures); WT neurons: 2.81 ± 1.14 ug mg (tau 656 
total protein) (n = 12 cultures); iPSC neurons: 6.05 ± 1.07 ug mg (tau per total protein) 657 
(n = 12 cultures). For seeding experiment, 2.5 µg of clone 1, or clone 9 lysates prepared 658 
as previously described were added to neurons that were transduced with RD P301S 659 
YFP at DIV 6-8, and cultured for an additional 9-10 days.  660 
Neural Induction.  iPSC were differentiated into cortical neurons.  Briefly, iPSC were 661 
converted to neural epithelium using the dual SMAD inhibitors dorsomorphin and 662 
SB431452, followed by an extended period of in vitro neurogenesis to generate cortical 663 
glutamatergic neurons.  Neurons were maintained in 1:1 mixture of N-2 medium and B-664 
27 medium33.  Medium was changed every 48 h.  Neuron-conditioned media were 665 
prepared by collecting media after 48 h, centrifuging at 3,000 x g for 10 min to remove 666 
cell debris and stored at -80 °C. 667 
Immunoprecipitation. Neurons were transduced with either tau-GFP or GFP (75,000 668 
neurons / well, tau-P301L-GFP, 2 x 109 particles, GFP, 2 x 109 particles).  Media from 669 
wild-type (wt), GFP expressing, or tau expressing cells was collected every 3-4 days 670 
from mature neurons (tau or tau-GFP, 14-21 DIV) and centrifuged at 3,000 x g for 10 671 
min at 4 °C to remove cell debris.  At the end of collection, cells were harvested in RIPA 672 
buffer with protease and phosphatase inhibitors (1 µg ml-1, Sigma).  For 673 
immunoprecipitation of tau, magnetic anti-mouse protein A dynabeads (Life 674 
Technologies) were incubated with human tau-specific antibody (CP27, mouse) at a 2:1 675 
ratio O/N, washed 3 times with 0.1% BSA in PBS and incubated with either conditioned 676 
media or cell lysates for 2 h at 4 °C.  Beads were isolated using a magnetic stir bar and 677 
resuspended in loading buffer for western blot analysis. 678 
Immunoblot. Immunoprecipitated samples were prepared and analyzed by immunoblot 679 
as previously described with the exception that membranes were probed with rabbit 680 
anti-tau (1:2000, Dako) and anti-actin (1:5000) antibodies.  For human iPSC western 681 
blot, cells were harvested in buffer containing protease and phosphastase inhibitors 682 
(Roche).  Equal amounts of protein were dephosphorylated using lambda protein 683 
phosphatase (NEB) prior to separation on 4-12% NuPage gels (Invitrogen).  684 
Recombinant tau ladder (Sigma) was used to identify specific tau isoforms.  Proteins 685 
were transferred to nitrocellulose membranes and blocked with 3% milk in PBS before 686 
incubation with anti-tau antibody (total tau, DAKO) O/N at 4 °C.  Membranes were 687 
incubated with IRDye 800 conjugated goat anti-rabbit (Rockland Inc) and proteins were 688 
visualized using the Odyssey Infrared imaging system (LiCor Biosciences). For western 689 
blot analysis of human iPSC neurons, cells were lysed in 10 mM Tris, pH 7.4, 100 mM 690 
NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 10% glycerol, 0.1% SDS, 0.5% 691 
deoxycholate, plus protease and phosphastase inhibitors (Roche) for 1h at 4 °C.  692 
Proteins were separated on SDS-PAGE BisTris gels (NuPAGE Novex, 4-12%, 693 
Invitrogen) and subsequently transferred onto nitrocellulose membranes.  Membranes 694 
were blocked in phosphate buffered saline containing 3% milk (PBS-M) for 1hr at RT.  695 
Membranes were incubated in primary antibody (DAKO polyclonal antibody to total tau, 696 
dilution 1:10,000) in PBS-M overnight at 4 °C.  Blots were developed with IRDye 800 697 
conjugated goat anti-rabbit (Rockland Inc) or IRDye 680 conjugated goat anti-mouse 698 
(Molecular Probes, Eugene, OR, USA) and visualized using an Odyssey Infrared 699 
Imaging System (Li-Cor Biosciences).  For analysis of tau isoforms, samples were 700 
dephosphorylated prior to electrophoresis using lambda protein phosphatase and 701 
separated by SDS-PAGE alongside a recombinant tau ladder (Sigma). 702 
Tau ELISA. Mature tau-KO-GFP neurons were exposed to tau-conditioned media for  6 703 
h, 12 h, 1 and 6 days, washed 3x with warmed PBS, trypsinized for 2 min, collected and 704 
homogenized in buffer supplemented with protease and phosphatase inhibitors at 4 °C. 705 
Protein concentration was determined by BCA Assay (Pierce) and normalized with 1 x 706 
PBS.  Sandwich ELISA was performed as previously described using tau monoclonal 707 
antibodies DA31 and DA9-HRP50.  708 
Viral vectors.  Tau RD-P301S YFP (aa 244-372 of the 441 full length tau, mutations 709 
P301S “PS”), YFP, mCherry viruses were prepared by transient co-transfection of 710 
HEK293T cells with indicated vectors using calcium phosphate method.  Media 711 
containing virus was collected at 48 h post transfection and purified using Lenti-X-712 
Concentrator according to manufacturer’s protocol (Clontech).  Wild type and P301L 713 
4R2N tau constructs were cloned into an eGFP-AAV1 vector (chicken beta-actin 714 
promoter), and all sequences were verified.  AAV was subsequently produced and the 715 
genomic titer of each virus was determined by quantitative PCR. 716 
RNA Extraction and Quantitative RT-PCR.  RNA was extracted from 5-10mg 717 
hippocampal tissue from three, 7 month old mice (rTg4510 line, male and female) that 718 
were optogenetically stimulated for 20 days as describe before, plus three 2-3 month 719 
old animals, stimulated for five days, using a standard trizol procedure.  SuperScript® III 720 
RT enzyme and SuperMix (InvitrogenTM, Carlsbad, CA) containing 2.5 µM oligo(dT)20, 721 
2.5 ng µl-1,  random hexamers, 10 nM MgCl2 and dNTPs, was used for first strand cDNA 722 
synthesis in a 20 µL reaction volume. Gene expression was assessed using TaqMan® 723 
probes (ThermoFisher Scientific, Waltham, MA) for the human tau transgene 724 
(Hs00902194_m1), mouse NeuN (Rbfox3) (Mm01248771_m1) and the mouse 725 
hypoxanthine guanine phosphoribosyl transferase gene (Hprt) (Mm03024075). PCRs 726 
were performed by monitoring in real time the increase in fluorescence of the FAM and 727 
VIC fluorophores, using an iQ5 detector system (Bio-Rad, Hercules, CA). All samples 728 
were run in triplicate 20 µL duplexed PCR reactions using 1 µL each of FAM and VIC 729 
labeled TaqMan® probes, 10 µL of TaqMan® Gene Expression Master Mix (Applied 730 
Biosystems, Foster City, CA), and 8 µL of diluted cDNA (1:40), using amplification 731 
conditions as follows: 50 °C for 2 mins, followed by 95 °C for 10 mins and 40 cycles of 732 
denaturation at 95 °C (15 s), and priming, extension and data capture 60 °C (60 s). A 733 
standard curve was generated for each gene using dilutions of cDNA pooled from each 734 
sample. Relative expression changes were calculated using the 2-∆∆CT method (Livak 735 
and Schmittgen, 2001), defined as the ∆CT of the sample normalized to the 736 
housekeeping gene Hprt, minus the ∆CT of the normalized reference sample from the 737 
standard curve.   738 
 739 
In vitro stimulation and cell viability assessment. To induce activity, neurons at 12-14 740 
DIV were treated with picrotoxin (100 µM) for 30 min without changing the medium.  For 741 
optogenetic stimulation, neurons were transduced with tau (tau-P301L-GFP, 2 x 109 742 
particles) and ChR2 (AAV9.CaMKIIa.hChR2(H134R)-mCherry.WPRE.hGH; Penn 743 
Vector Core, 3.98 x 1011 particles) at 3-5 DIV. After 9-12 DIV, control wild type or 744 
transduced neuronal cultures were placed on an upright microscope (Olympus) and 745 
stimulated with blue light (470 nm) at 0.1 mW mm-2 (40 mA) for 30 min at 2 sec 746 
intervals.  The emission power was measured using a power meter (ThorLabs) that is 747 
placed directly below, and at the same distance from the objective lens as the cultures.  748 
The chamber temperature was maintained at 32 °C ± 2 °C. Media was collected before 749 
and after stimulation, centrifuged to remove cell debris, and analyzed by Sandwich 750 
ELISA using tau monoclonal antibodies DA31 and DA9-HRP50 in duplicates. Cell death 751 
was quantified by measuring LDH release in the same neuronal populations prior to, 752 
and after treatments, according to manufacturer’s protocol (Promega). Each experiment 753 
was performed three times in triplicates (n = 6). 754 
Whole-cell patch clamp recordings.  Mature neuronal cultures (DIV 12-14) were placed 755 
on the recording chamber (Warner Instruments) of an upright microscope equipped with 756 
a 10 x and a 40 x oil-immersion objectives (Olympus).  Control and transduced neurons 757 
were identified by DIC optics and fluorescences, respectively.  Cells were perfused with 758 
artificial cerebrospinal fluid (ACSF) containing (in mM): 119 NaCl, 26.2 NaHCO3, 10 759 
glucose, 2.4 CaCl2, 3.6 KCl, 1.2 MgCl2-6H20, and 1.0 NaH2PO4-6H20 at < 0.5 ml min-1 760 
flow rate. The chamber temperature was maintained at 32 °C ± 2 °C. Whole-cell patch 761 
clamp recordings were made with pulled borosilicate glass pipettes (G150F-4, Warner 762 
Instruments, tip resistance 2-4 MΩ) filled with intracellular solution containing (in mM): 763 
115 K-gluconate, 20 KCl, 10 HEPES, 2 MgCl2, 2 ATP-Mg, 2 ATP-Na2, 0.3 GTP-Na, 764 
(pH=7.25, ~300 mOsm). Whole cell current clamp recording were performed with an 765 
Axopatch 200B amplifier (Molecular Devices) and digitized at 10 kHz with a Digidata 766 
1332 (Molecular Devices).  Data were acquired using Clampex 8.2 software (Molecular 767 
Devices) for subsequent analysis. Blue light (470 nm) or control red light (545 ± 30 nm) 768 
were delivered by an LED controller (Thorlabs, 40 mA) and triggered with a Master-8 769 
pulse generator (A.M.P.I. Labs). Synaptic inputs were blocked with picrotoxin (50 µM) 770 
and NBQX (20 µM) (Sigma Aldrich). The input resistance and the baseline resting 771 
membrane potential were monitored throughout the recording. Current-voltage 772 
relationships were measured by injecting step current from -300 to + 150 pA with + 50 773 
pA increments.  Data were analyzed in Clampfit (Molecular Devices). 774 
Surgery.  Surgical procedures were performed following NIH guidelines in accordance 775 
with IACUC protocols.  Mice were anesthetized with ketamine/xylazine (100 mg ml-1, 15 776 
mg ml-1, respectively).  AAV5 CamKII.hM3Dq-mCherry (1.7 x 1012 particles) and 777 
AAV9/CamKIIa.hChR2-mCherry (2 x 1012 particles) virus was injected into the MEC 778 
(0.2-0.3 mm in front of the transverse sinus (AP), 3.0-3.1 mm (ML), and 1.5 mm below 779 
the dura (DV), line rTg4510) of the left, or right hemisphere of the mice respectively.  780 
For in vivo optogenetic experiments, AAV9/CamKIIa.hChR2-mCherry (2 x 1012 781 
particles) virus was injected into the hippocampus (1.5 mm (DV), 1.8 mm (ML), 1.8 mm 782 
(AP)) of both the left and right hemispheres of the mice (line rTg4510).  A 20 mm 783 
cannula was implanted slightly above the injection site (~1.2 mm) in both brain 784 
hemispheres.  For one mouse, a microdrive was implanted in the left hemisphere (~1.2 785 
mm depth) to record neuronal activity. Dental cement was used to secure the cannulae 786 
and microdrive.   787 
In vivo chemogenetic stimulation and electrophysiology.  Ten days following viral 788 
DREADD transduction, clozapine-N-oxide (CNO) was given to mice systemically via 789 
intraperitoneal injections at 5 mg kg-1, two times per day (6 - 7 hrs in between 790 
injections), five days per week for either two or six weeks.  Total stimulation was either 791 
20 or 60 times.   IP injections were alternated between left and right sides of the mouse 792 
to minimize scarring. CNO (C-929) was generously provided by the National Institutes 793 
of Mental Health Chemical Synthesis and Drug Supply Program.  Both male and female 794 
mice were used. 795 
 796 
In vivo optogenetic stimulation and electrophysiology. Ten days following ChR2 viral 797 
transduction, the left hemisphere of mice was optically stimulated with four pulses of 798 
LED light (470 nm) (Thorlabs) at 30 Hz frequency, three times with one -minute interval.  799 
Mice were stimulated three times per day, five times per week for four weeks (60 800 
stimulations total).  The right hemisphere was not stimulated to provide a within-animal 801 
control. To record neuronal activity, the mouse implanted with electrodes was plugged 802 
into the electrophysiology setup (Axona) during stimulation and neuronal activity was 803 
recorded. Individual neurons from the recording data were separated using the spike 804 
sorting software Tint (Axona). Neurons were identified based on spike- firing rate, 805 
amplitude, waveform and their refractory periods. sigTOOL (a Matlab-based signal 806 
analysis tool) was used to visualize changes in neuronal firing during optical stimulation.  807 
Both male and female mice were used. 808 
 809 
Immunofluorescence, Nissl and DAB staining.  Mouse brains were collected as 810 
described previously.  Free-floating sections in either coronal or horizontal plane (35 811 
µm) were used for immunofluorescence.  Human iPSC neurons were grown in 8-well 812 
chamber slides (Ibidi) and primary neurons were grown as previously described.  813 
Neurons and free-floating tissues were immunolabeled and mounted as previously 814 
described with the following antibodies: mouse anti-tau (CP27, 1:1000, MC1, 1:2000, 815 
(gifts of P. Davies)), rabbit anti-GFP (1:500, abcam), total Tau (DAKO, 1:5000), 3R tau 816 
(RD3, Millipore, 1:1000), Pax6 (Covance, 1:300), Ki67 (BD Biosciences, 1:500).  817 
Fluorescent-conjugated secondary antisera mixtures containing Alexa 488 IgG, Alexa 818 
594 IgG, or Alexa 657 IgG (Invitrogen) were used.  Antigen retrieval was performed on 819 
tissues by heating in sodium citrate for 5 min at 95 °C.  Tissues were treated with sudan 820 
black (0.1% in PBS) for 10 - 15 min to eliminate autofluorescence from lipofuscin.  For 821 
Nissl staining, sections were stained with 0.1% cresyl violet in 70% EtOH for 10 min at 822 
RT, rinsed with distilled H20, washed three times with PBS and mounted with Prolong 823 
anti-fade medium (Invitrogen). DAB staining on tissues was performed as previously 824 
described2.  Briefly, tissues were treated with 5% H2O2 in PBS for 10 minutes to quench 825 
endogenous peroxidase activity, blocked in PBS containing 5% horse serum and 0.3% 826 
Triton, and incubated at 4 °C overnight as previously described2 with the following 827 
antibodies: c-Fos (1:200, Santa Cruz, G3115), AT8 (S202/205, 1:1000, ThermoFisher, 828 
MN1020), MC1 (conformationally abnormal human tau, 1:1000).  After three washes 829 
with PBS-T, tissues were developed using Super Picture HRP (Invitrogen) for 15 mins 830 
at room temperature on a rotator and detection of the chromagen with DAB (Sigma-831 
Aldrich) was done according to the manufacturer’s manual.  In the case of c-Fos 832 
staining, mice were sacrificed 75 minutes after their last CNO injection. ABC kit 833 
(Vectastain, Vector Labs) was used to develop the tissues according to the 834 
manufacturers manual.  The sections were mounted, and visualized by light 835 
microscopy.  836 
Confocal and light microscopy. Immunolabeled neurons and tissues were examined 837 
with a Zeiss LSM710 confocal microscope at 10x dry and 63x oil immersion objectives 838 
as previously described.  Sequential tile scans were performed to capture wide field 839 
images of microfluidics (at 1024 x 1024 resolution) and tissues (512 x 512).  Sequential 840 
scans were performed to capture images of cells grown on coverslips (1024 x 1024).  841 
All images from the same experiment were taken at the same laser intensity and 842 
detector gain.  3D co-localization analysis was performed using Volocity 4.0 Restoration 843 
software (Volocity, Improvision).  All DAB sections were examined with a Zeiss 844 
AxioObserver.Z1 inverted microscope at 10x. Sequential tile scans were performed to 845 
capture wide field images of the whole section at 10x.  Immunofluorescent images of 846 
co-culture experiments were captured at 20x magnification, 10 images per coverslip at 847 
either 512 x 512 resolution or 1024 x 1024 resolution, randomized and quantified by a 848 
technician who did not know the identity of the samples (n = 2 coverslips, 10 images per 849 
coverslip). 850 
 851 
Statistical analyses and sample sizes.  Statistical analyses were performed using 852 
GraphPad Prism 5.0 (Graph Pad Software, La Jolla, CA, USA) and Stata 12.1 (College 853 
Station, TX). No statistical methods were used to predetermine sample sizes, but our 854 
sample sizes are similar to those previously reported22. Normality of the data and 855 
homogeneity of group variances were assessed using the Shapiro-Wilk W test and 856 
Levine’s test respectively.  When assumptions were not met or sample sizes were 857 
insufficient to test assumptions, non-parametric tests were employed.  Adjustments 858 
were made for multiple testing under each hypothesis, via Bonferroni correction.  859 
Statistical significance was determined if adjusted p < 0.05.  Data are represented in dot 860 
plot graphs with mean ± s.e.m. To investigate tau uptake into recipient neurons via the 861 
extracellular media we measured tau levels in neurons from MAPT -/- (knock out) mice 862 
at baseline (no incubation, n = 4 coverslips), 1 - 6 hours after the conditioned media was 863 
added  (n = 6 independent coverslips), and 1 - 6 days after addition of conditioned 864 
media (n = 4 independent coverslips).  A Wilcoxon rank-sum test was employed to test 865 
for differences in the levels of tau, comparing tau levels at baseline levels with levels at 866 
6 hours or less, and tau at baseline with levels at 1 - 6 days.  To examine whether tau 867 
release is enhanced following neural activity in vitro, primary neurons were stimulated 868 
with picrotoxin. Levels of mouse tau in wt neurons (mTau) (n = 9 separate coverslips), 869 
mouse tau plus human tau in rTg4510 neurons (mTau+ hTau) (n = 9 separate 870 
coverslips) and human tau in iPSC cultures (hTau) (n = 6 separate coverslips) was 871 
assessed.  For each model, additional and independent cultures (mTau n = 9; mtau + 872 
hTau n = 9;  hTau n = 6) were utilized as the non-stimulated control group. Experiments 873 
were performed over two days, with 50% of the independent samples assessed on each 874 
experimental day.  Samples were analyzed as a single group (regardless of 875 
experimental day), using individual Student t-tests (with Satterthwaite's approximation 876 
for unequal group variance) to determine differences between control and picrotoxin 877 
treatment in the three models.  In vitro optogenetic stimulation was performed using four 878 
separate cultures for each of three experimental conditions: control, non-stimulated ChR 879 
and simulated ChR.  Differences in tau release across conditions was tested using a 880 
Kruskal-Wallis omnibus test, followed by Dunn’s post hoc tests with a Bonferroni 881 
correction.  To test the hypothesis that transfer of tau is enhanced by stimulating 882 
neuronal activity, the percent of recipient neurons with human tau from the donor was 883 
calculated (the number of cells expressing mCherry that were YFP positive / total 884 
mCherry positive cells x 100%).  For each condition (stimulated and non-stimulated), 885 
neurons were plated on n = 5 independent coverslips.  To obtain an accurate 886 
representation of neurons across each coverslip, multiple images were used for cell 887 
counting.  The percent of total neurons with tau transferred from the donor were 888 
compared between stimulated and non-stimulated conditions using a Student’s t-test. 889 
Gene expression (Supplementary Figure 1) was compared between the 890 
optogenetically stimulated side of the hippocampus (S, n = 6 animals) and the non-891 
stimulated sides (NS, n = 6 animals), using a paired sample t-test. To test the 892 
hypothesis that atrophy due to stimulation would be significantly different in the tau mice 893 
(n = 4), as compared to tau-KO mice (n = 4), left and right cell body layers in the 894 
hippocampus were measured in Nissl-stained sections using ImageJ. Nissl signal above 895 
threshold levels were compared between the regions of interest on each side of the 896 
brain slice. The threshold value was kept the same between slices, within an animal. 897 
The value for the left, stimulated hippocampus was divided by the right, non-stimulated 898 
hippocampus to obtain a ratio of left divided by right signal in each slice. Ratios of all 899 
slices from each animal were averaged. A Wilcoxon rank-sum test was employed to 900 
compare the ratio of left/right staining across mouse groups.  The Wilcoxon-rank test 901 
statistic would be expected to approximate to the normal distribution with this sample 902 
size.  In figures, calculated probabilities are symbolized by asterisks as follows: *P < 903 
0.05; **P < 0.0; *** P < 0.001.  Optogenetic stimulation and immunoflorescent image 904 
analysis was performed by a blinded observer. Other blinded authors analyzed DAB 905 
and immunofluorescent stains of brain tissues (non-stimulated hemisphere versus 906 
stimulated hemisphere). Statistical analysis was not performed blinded to the 907 
experimental conditions. For optogenetic and chemogenetic experiments, mice of the 908 
appropriate age were selected from several different litters and randomly assigned as 909 
control or experimental. No other randomization in experimental conditions or stimulus 910 
presentations was performed. 911 
 912 
A Supplementary Methods Checklist is available.  913 
 914 
Data Availability 915 
The data that support the findings of this study are available from the corresponding 916 
author upon request.  The authors declare that data supporting the findings of this study 917 
are available within the article.  Source data for figures 4b, 5a, b, g, h, 6b, and 7h are 918 
provided within the article.   919 








